Loading clinical trials...
Loading clinical trials...
1. Describe the risk factors and metabonomics characteristics of atherosclerotic cardiovascular disease in Chinese patients. 2. Establish accurate prediction model of atherosclerotic heart disease.
According to the Chinese cardiovascular disease report released in 2017, cardiovascular disease death is the leading cause of death of urban and rural residents, so cardiovascular disease risk assessment is particularly important. The development of cardiovascular risk assessment model was dated from Framingham Heart Study which first proposed the concept of risk factors, and then adjusted the model several times. In 2016, the China-PAR evaluated the cardiovascular disease risk of Chinese population. However, the application of metabolomics in coronary heart disease is a rapidly developing field and also a new field . Therefore, the aim of this study was to 1.Describe the risk factors of atherosclerotic cardiovascular disease and the characteristics of metabolomics in Chinese population. 2\. Establish an accurate prediction model of atherosclerotic heart disease. Research plan: 1. 1869 risk-stratified people were recruited. 2. Plasma samples were collected incluing disease status and other potential influencing factors. 3. Through the high-throughput detection of body metabolites, combined with multivariate statistical analysis, the metabolic markers with significant difference in different risk levels were screened for risk prediction. 4. All recruited people underwent coronary angiography. 5. The distribution of age and gender in each group should be matched and balanced as far as possible.
Age
18 - 90 years
Sex
ALL
Healthy Volunteers
Yes
Department of Cardiology,Shanghai Tenth People's Hospital
Shanghai, China
Shanghai Tenth People's Hospital
Shanghai, China
Start Date
December 15, 2021
Primary Completion Date
December 15, 2024
Completion Date
December 15, 2024
Last Updated
December 8, 2021
1,869
ESTIMATED participants
Lead Sponsor
Shanghai 10th People's Hospital
NCT07241390
NCT01143454
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions